Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Pharmacotherapy

Pasireotide for uncontrolled acromegaly—new phase III trial data

Nature Reviews Endocrinology volume 10, page 700 (2014)Cite this article

Subjects

Access through your institution
Buy or subscribe

Results from a phase III clinical trial show that pasireotide long-acting release (LAR) is more effective than either octreotide or lanreotide for treating patients with acromegaly, supporting use of pasireotide LAR for patients with disease that is inadequately controlled by first-generation somatostatin analogues.

Octreotide and lanreotide are the current first-line therapies for acromegaly; however, these treatments are estimated to leave as many as 30–80% of patients with inadequately controlled levels of circulating growth hormone and insulin-like growth factor 1 (IGF-1).

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gadelha, M. R. et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10.1016/S2213-8587(14)70169-X

Download references

Authors
  1. Jennifer Sargent
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sargent, J. Pasireotide for uncontrolled acromegaly—new phase III trial data. Nat Rev Endocrinol 10, 700 (2014). https://doi.org/10.1038/nrendo.2014.176

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2014.176

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing